Eddie Hickman
Stock Analyst at Guggenheim
(4.52)
# 276
Out of 5,112 analysts
20
Total ratings
68.42%
Success rate
22.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYBN Cybin | Maintains: Buy | $39 → $48 | $6.79 | +606.92% | 2 | Dec 3, 2025 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $150 → $125 | $8.92 | +1,301.35% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $77.77 | +11.87% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $2.27 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.11 | +171.27% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $12.69 | +152.17% | 1 | Mar 13, 2025 |
Cybin
Dec 3, 2025
Maintains: Buy
Price Target: $39 → $48
Current: $6.79
Upside: +606.92%
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $150 → $125
Current: $8.92
Upside: +1,301.35%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $77.77
Upside: +11.87%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.27
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.11
Upside: +171.27%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $12.69
Upside: +152.17%